Phase 2b RCT in 393 biologic-naive adults with moderate-to-severe atopic dermatitis: all three rezpegaldesleukin doses reduced EASI more than placebo at week 16 (mean −53% to −61% vs −31%; p≤0.0002). Injection-site reactions occurred in 70% vs 4%.
RCTn = 393
Silverberg et al. Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study